Vanguard Capital Management’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
Other funds holding TSHA
SL
Vanguard Capital Management's TSHA Position: Q3 2026 in Review
Vanguard Capital Management increased its Taysha Gene Therapies (TSHA) stake by 0.49% in Q3 2026, buying an estimated $354K and bringing the position to 12,540,069 shares worth $61.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1793.
Vanguard Capital Management first reported a position in TSHA in Q1 2026 and has held it in 3 quarters since. The position peaked at $85M in Q2 2026. 205 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.
- Vanguard Capital Management held 12,540,069 shares of Taysha Gene Therapies worth $61.1M as of Q3 2026.
- Vanguard Capital Management bought 61,474 Taysha Gene Therapies shares in Q3 2026, an estimated $354K.
- Taysha Gene Therapies made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1793 holding.
- Vanguard Capital Management first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Taysha Gene Therapies position peaked at $85M in Q2 2026.
- 205 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.